

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



EP00/1457

The
Patent
Office

PCT/EP+ 00/01457

REC'D 29 MAR 2000

WIPO PCT



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

EPO - DG 1

13. 03. 2000

(74)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

Andrew Gervay

Dated 2 December 1999

PAGE BLANK (USPTO)

For Official use



25 FEB 1999

Your Reference: RE/RH/ B45171

26FEB99 E428455-3 D02029
P01/7700 0.00 - 9904412.5

9904412.5

Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-483 4700).

**The
Patent
Office**

Request for grant of a

Patent

Form 1/77

Patents Act 1977

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

- ② Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

① Title of invention

1 Please give the title of the invention Vaccine

② Applicant's details
☐ First or only applicant

2a If you are applying as a corporate body please give:
Corporate Name SmithKline Beecham Biologicals
s.a.

Country (and State of incorporation, if appropriate) Belgium

2b If you are applying as an individual or one of a partnership please give in full:

Surname
Forenames

2c In all cases, please give the following details:

Address: rue de l'Institut 89, B-1330 Rixensart, Belgium

UK postcode
(if applicable)

Country Belgium
ADP number 5800974002
(if known)

578 111 1001

2d, 2e and 2f: If there are further applicants please provide details on a separate sheet of paper



Second applicant (if any)

2d

If you are applying as a corporate body please give:

Corporate Name

Country (and State of
Incorporation, if appropriate)

2e

If you are applying as an individual or one of a partnership please give in full:

Surname:

Forenames:

2f

In all cases, please give the following details:

Address:

UK postcode

(if applicable)

Country

ADP number

(if known)

3

An address for service in the United Kingdom must be supplied

Please mark correct box.

3

Address for service details

3a

Have you appointed an agent to deal with your application?

Yes ☒

No ☐ go to 3b



please give details below

Agent's name MARCUS J W DALTON

Agent's address SmithKline Beecham
Corporate Intellectual Property
Two New Horizons Court
Brentford, Middlesex
TW8 9EP

Postcode

Agent's ADP
number

4122313005

3b: If you have appointed an agent, all correspondence concerning your application will be sent to the agent's United Kingdom address.

3b

If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Postcode
number

ADP number
(if known)

Daytime telephone
(if available)

Reference number

4. Agent's or
applicant's reference RE/RH/ B45171
number (if applicable)

5 Claiming an earlier application date

5. Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Yes ☐

No ☒ go to 6



please give details below

☐ number of earlier
application or patent
number

☐ filing date (day month year)

☐ and the Section of the Patents Act 1977 under which you are
claiming:

15(4) (Divisional) ☐ 8(3) ☐ 12(6) ☐ 37(4) ☐

6 Declaration of priority

6. If you are declaring priority from previous application(s), please give:

Country of Filing

Priority application
number
(if known)

Filing Date
(day, month, year)

Please mark correct box

Please mark correct box

6 If you are declaring priority from a
PCT Application please enter 'PCT'
as the country and enter the country
code (for example, GB) as part of
the application number

*Please give the date in all number
format, for example, 31/05/90 for
31 May 1990*

7

- any applicant is not an inventor
- there is an inventor who is not
 - an applicant, or
 - any applicant is a corporate body.

- 8 Please supply duplicates of claim(s), abstract, description and drawings).

Please mark correct box(es)

- 9 You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here **a**

A completed fee sheet should preferably accompany the fee.

7 Inventorship

7. Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark correct box

Yes ☐ No ☒

A Statement of Inventorship on Patents form 7/77 will need to be filed (see Rule 15).).

8 Checklist

- 8a Please fill in the number of sheets for each of the following types of document contained in this application

Continuation sheets for this Patents Form 1/77

—

Claim(s) 1 Description 28

Abstract Drawing(s) 4 *encl.*

- 8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

—

Translation(s) of Priority documents (please state how many)

—

Patents Form 7/77 - Statement of Inventorship and Right to Grant

—

Patents Form 9/77 - Preliminary Examination Report

—

Patents Form 10/77 - Request for Substantive Examination

—

9 Request

I/We request the grant of a patent on the basis of this application.

Signed

Marcus J W Dalton
MARCUS J W DALTON

Date: 25/02/99

(day month)

year)

Chartered Patent Attorney

Attorney for the Applicant

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to either;

☐ The Comptroller or
The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

☒ The Comptroller
The Patent Office
25 Southampton Buildings
London
WC2A 1AY

Vaccine

The present invention relates to immunogens comprising a peptide and a carrier, in particular when the carrier is derived from Haemophilus Influenzae Protein D. The immunogens of the present invention may be used in pharmaceutical compositions for the prophylaxis or therapy of disease, especially in the form of vaccines. The invention further relates to their production, pharmaceutical compositions containing them, and their use in medicine.

Immunogens comprising short peptides are becoming increasingly common in the field of vaccine prophylaxis or therapy. The peptides which are commonly used may be the full length native immunogen, for example human peptidic hormones, or may be fragments of a larger antigen derived from a given pathogen, or from a large self-protein.

15

In many disease states it is often possible, and desirable, to design vaccines comprising a short peptide rather than the large protein. For example, immunoprophylaxis of allergy may beneficially comprise the use of short peptides of IgE (EP 0 477 231 B1), whereas the use of IgE itself as the immunogen may induce anaphylactic shock. In addition, a number of authors have described the use of the whole length Gonadotrophin hormone releasing hormone (GnRH, WO 95/20600), a short 10 amino acid long peptide, in the treatment of many cancers, or in immunocastration.

Amongst the problems associated with the peptide approach to vaccination, is the fact that peptides *per se* are poor immunogens. Generally the sequence of the peptides are chosen such that they include a B-cell epitope to provide a target for the generation of anti-peptide antibody responses, but because of their limited size rarely encompass sufficient T-cell epitopes in order to provide the necessary cytokine help in the induction of strong B-cell responses. Strategies which have been designed to overcome this lack of immunogenicity include the linking of the peptide to large

highly immunogenic protein carriers, which provide bystander T-cell help, and/or the use of strong adjuvants in the vaccine formulation.

5 Examples of these highly immunogenic carriers which are currently commonly used for the production of peptide immunogens include the Diphtheria and Tetanus toxoids (DT and TT respectively), Keyhole Limpet Haemocyanin (KLH), and the purified protein derivative of Tuberculin (PPD). A number of problems are associated with each of these commonly used carriers, including both problems in production of GMP
10 constructs and also in immunological characteristics of the constructs. The present invention provides a new carrier for use in the preparation of peptide-based immunogen constructs, that does not suffer from the aforementioned disadvantages.

However, despite the common use of these carriers and their success in the induction of high anti-peptide antibody responses they are associated with several drawbacks.
15 For example, it is known that antigen specific immune responses may be suppressed by the presence of preexisting antibodies directed against the carrier, in this case Tetanus toxin (Di John *et al*; Lancet, December 16, 1989). In the population at large, a very high percentage of people will have pre-existing immunity to both DT and TT as people are routinely vaccinated with these antigens. In the UK for example 95% of
20 children receive the DTP vaccine comprising both DT and TT. Other authors have described the problem of epitope suppression to peptide vaccines in animal models (Sad *et al*, Immunology, 1991; 74:223-227; Schutze *et al*, J. Immunol. 135: 4, 1985; 2319-2322).

25 In addition, for vaccine which require regular boosting the use of highly immunogenic carriers such as TT and DT are likely to suppress the peptide antibody response after several injections. These multiple vaccinations may also be accompanied by undesirable reactions such as delayed type hyperresponsiveness (DTH).

30 KLH is known as potent immunogen and has already been used as a carrier for IgE peptides in human clinical trials. However, some adverse reactions (DTH-like

reactions or IgE sensitisation) as well as antibody responses against KLH which could compete with the anti-decapeptide antibody have been observed.

5 The selection of a carrier protein, therefore, for a peptide based vaccine will require a balance between the necessity to use a carrier working in all patients (broad MHC recognition) and the induction of high levels of anti-peptide antibody responses and of low antibody response against the carrier.

10 The carriers used previously for peptide based vaccines, whilst they may induce high levels of anti-peptide antibody responses on primary immunisation, therefore have many disadvantages.

The present invention provides a protein D from Haemophilus Influenzae, or fragments thereof, as a carrier for peptide based vaccines which induces high anti-peptide immune responses with a moderate or low anti-carrier response.


15 One of the fields of research where a great deal of effort has been made in designing peptide based vaccines in the prophylaxis and therapy of allergic responses. In a response to allergens, the symptoms of an allergic response are brought about by the release of mediators (such as histamine) from immune cells into the surrounding tissues and vascular structures. Histamine is normally stored in mast cells or basophils, until such time as the release is triggered by interaction with allergen specific IgE.

20 The role of IgE in the mediation of allergic responses, such as asthma, food allergies, type-I hypersensitivity and sinus inflammation, is well known. On encountering an antigen, such as pollen or dust mite allergens, B cells commence the synthesis of allergen specific IgE. The allergen specific IgE then binds to its FcεRI receptor (the high affinity receptor) on basophils and mast cells. Any subsequent encounter with allergen leads to the triggering of histamine release from the mast cells or basophils, and cross-linking of neighbouring IgE/ FcεRI complexes (EP 0 477 231 B1).

A number of passive or active immunotherapeutic and immunoprophylactic approaches which interfere with this IgE-mediated histamine release mechanism have been investigated. These approaches include the use of specific IgE peptides for active immunisation, in order to stimulate auto anti-IgE antibodies which are capable of
 5 inhibiting histamine release by interfering with the IgE-mediated trigger signal.

EP 0 477 231 B1 describes one such approach. Peptides derived from the Cε4 domain of IgE (residues 497-506, also known as the Stanworth decapeptide), conjugated to Keyhole Limpet Haemocyanin (KLH). A number of carriers for the IgE peptides are
 10 suggested including KLH, Tetanus toxoid, Diphtheria toxoid, albumins, haemocyanins such as Keyhole Limpet Haemocyanin (KLH), polymers of amino acids, and preferably purified protein derivative of tuberculin (PPD).

WO 95/26365 further continues investigation of the Cε4 (497-506) peptide and
 15 describes immunogens which is rendered substantially free of carrier protein by the addition of universal T-helper epitopes. The immunogens of WO 95/26365 are in the general formula:



where A is an amino acid; Th is a T-helper epitope; B is an amino acid; and Stan is
 20 the Stanworth decapeptide. n=1 to 10; m=1 to 4; o=0 to 10; and p=1 to 3.

WO 98/24808 describes oligopeptides derived from Cε3, which interact with the high or low affinity receptors of IgE. These oligopeptides are expressed as fusion proteins together with the expression partner Glutathione-S-transferase (GST). WO 97/31948
 25 describes IgE peptide immunogens conjugated to a protein carrier, the carriers described are TT, DT, KLH and PPD.

Another important area for peptide vaccine research has been in the field of human peptide hormone vaccines. For example the peptide hormone, Gonadotrophin
 30 hormone releasing hormone (GnRH) has been used for the immunotherapy of Gonadal Steroid Hormone dependent diseases, such as many cancers (including prostate cancer) and immunocontraception. WO 95/20600 describes the use of GnRH

conjugated to a carrier protein in order to render it immunogenic. The example of a carrier used in the examples is Diphtheria toxoid (DT).

Other work in the art use similar carriers including PPD, TT, DT and the DT
5 derivative, CRM197, bovine serum albumin (BSA), Equine Serum Albumin (ESA),
Equine gamma globulin, Ovalbumin (OVA) Keyhole Limpet Haemocyanin (KLH),
porcine thyroglobulin, bacterial adhesins, viral haemagglutinin, hepatitis B surface
antigen, bacterial toxin such as LTB, outer membrane lipoprotein of *E. Coli*, TraT
protein, leukotoxin polypeptide, Pseudomonas exotoxin protein PE38QQR (EP 0 293
10 530 A2; EP 0 181 236 B1; WO 90/03182; EP 0 222 835 B1; EP 0 446 313 B1; WO
96/24675; US 5,324,512; US 4,975,420; WO 97/15316 WO 97/15325; WO 97/15317;
WO 90/02187)

The present invention overcomes these problems associated with peptide carriers of
15 the prior art. The problems are surprisingly overcome by the use of Protein D as a
peptide carrier for the preparation of immunogens.

Protein D is an IgD-binding protein from *Haemophilus influenzae* and has been
patented by Forsgren WO 91/18926 (EP 0 594 610 B1). The patent describes the
20 cloning, expression, and protein sequence of Protein D. It suggests its uses could be
methods of detecting IgD using its selective affinity for IgD (as for Protein A and
Protein G) and in the stimulation of the immune system through interaction with B-
lymphocytes.

25 EP 0 594 610 B1 further describes the Protein D gene, and suggests that it may be
fused to other genes and expressed to form fusion proteins. Furthermore, the
recombinant protein D or fusion proteins may be covalently linked to other proteins,
carbohydrate or particulate matrices.

30 Akkoyunlu et al. (Infection and Immunity, 1997, 65, 12, 5010-5016) and Akkoyunlu
et al. (Infection and Immunity, 1996, 64, 11 4586-4592) describe the large scale

purification of the non-acylated form of Protein D, and its use in vaccines. Immunised mice and rats had high levels of bactericidal protein D specific IgA and IgG.

The present invention provides the use of protein D as a carrier for peptide
5 immunogens. Said immunogens have the advantage of inducing high levels of anti-peptide immune responses whilst inducing a moderate humoral response against itself. In the context of an allergy vaccine, protein D as a carrier has the additional advantage of inducing low IgE responses in comparison to known carriers, such as KLH. In
10 some circumstances, for example, in recombinant expression systems it may be desirable to use fragments of protein D, for example protein D 1/3rd (comprising the N-terminus 100-110 amino acids of protein D (GB 9717953.5)). Accordingly there is also provided by the present invention a nucleic acid encoding protein D or fragment thereof and a peptide immunogen for use in expression systems for the manufacture of an immunogen.

15

The immunogens of the present invention, therefore, comprise a peptide conjugated to protein D as a carrier.

The term "peptide" within the meaning of the present invention is a polymer of amino
20 acids joined by peptide bonds, containing a sequence of amino acids preferably between 2-50 amino acids in length, and more preferably between 2-30 amino acids in length, and most preferably between 5-25 amino acids in length. The peptides of the present invention may be either lipidated or non-lipidated.

25 The peptides may be full length sequences of naturally occurring peptides like peptide hormones. Alternatively, the peptides may be derived from naturally occurring self proteins or proteins derived from pathogens.

Particularly preferred examples of peptides for use in immunogens of the present
30 invention include GnRH or mimetopes thereof: EHWSYGLRPG.

Most preferably the peptides are derived from mammalian IgE, such that the immunogens are capable of stimulating a non-anaphylactic anti-IgE antibody response in a vaccinated individual. For example, the stanworth decapeptides as described in EP 0 477 231 B1, for example KTKGSGFFVF or mimetopes thereof. Other IgE
5 peptides are described in WO 97/31948 and WO 96/14333, and are useful in immunogens of the present invention.

The present invention, therefore, includes the native peptides themselves, and any mimetope thereof. The meaning of mimetope is defined as a peptide sequence which
10 is sufficiently similar to the native peptide (sequentially or structurally), which is capable of being recognised by antibodies which recognise the native peptide; or are capable of raising antibodies, when coupled to a suitable carrier, which antibodies are capable of recognising the native peptide.

15 Peptide mimetopes may be designed for a particular purpose by addition, deletion or substitution of elected amino acids. Thus, the peptides may be modified for the purposes of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine. In addition it may be desirable for peptides conjugated to a protein carrier to include a hydrophobic
20 terminus distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein. Thereby presenting the peptide in a conformation which most closely resembles that of the peptide as found in the context of the whole native molecule.

25 The immunogens of the present invention may alternatively contain a peptide capable of eliciting an immune response against a human pathogen. Such peptides may be derived from the following group: an HIV antigen (such as tat, nef, gp120 or gp160), a human herpes virus antigen (such as gD or derivatives thereof or Immediate Early protein such as ICP27 from HSV1 or HSV2), a cytomegalovirus antigen (such as gB
30 or derivatives thereof), a Rotavirus antigen, an Epstein Barr virus antigen (such as gp350), Varicella Zoster Virus antigens (such as gpI, II and IE63), or from a hepatitis virus such as hepatitis B virus (for example Hepatitis B Surface antigen), hepatitis A

virus antigen, hepatitis C virus and hepatitis E virus, or from other viral pathogens, such as paramyxoviruses: Respiratory Syncytial virus (such as F and G proteins), parainfluenza virus, measles virus, mumps virus, human papilloma viruses (for example HPV6, 11, 16, 18), flaviviruses (e.g. Yellow Fever Virus, Dengue Virus,

5 Tick-borne encephalitis virus, Japanese Encephalitis Virus) or Influenza virus antigens, or peptides derived from bacterial pathogens such as *Neisseria spp.*, including *N. gonorrhea* and *N. meningitidis* (for transferrin-binding proteins, lactoferrin binding proteins, PilC, adhesins); *Streptococcus spp.*, including *S. pneumoniae* (streptolysin or choline-binding proteins), *S. pyogenes* (for example M

10 proteins, C5A protease), *S. agalactiae*, *S. mutans*; *Haemophilus spp.*, including *H. influenzae* type B, non typeable *H. influenzae* (for example OMP26, high molecular weight adhesins, P5, P6), *H. ducreyi*; *Moraxella spp.*, including *M. catarrhalis*, also known as *Branhamella catarrhalis* (for example high and low molecular weight adhesins and invasins); *Bordetella spp.*, including *B. pertussis* (for example pertactin,

15 pertussis toxin, filamentous hemagglutinin, adenylate cyclase, fimbriae), *B. parapertussis* and *B. bronchiseptica*; *Mycobacterium spp.*, including *M. tuberculosis* (for example ESAT6, Antigen 85A, -B or -C), *M. bovis*, *M. leprae*, *M. avium*, *M. paratuberculosis*, *M. smegmatis*; *Legionella spp.*, including *L. pneumophila*; *Escherichia spp.*, including enterotoxigenic *E. coli* (for example colonization factors, heat-

20 labile toxin or derivatives thereof, heat-stable toxin or derivatives thereof), enterohemorrhagic *E. coli*, enteropathogenic *E. coli* (for example shiga toxin-like toxin or derivatives thereof); *Vibrio spp.*, including *V. cholera* (for example cholera toxin or derivatives thereof); *Shigella spp.*, including *S. sonnei*, *S. dysenteriae*, *S. flexnerii*; *Yersinia spp.*, including *Y. enterocolitica* (for example a Yop protein), *Y. pestis*, *Y.*

25 *pseudotuberculosis*; *Campylobacter spp.*, including *C. jejuni* (for example toxins, adhesins and invasins) and *C. coli*; *Salmonella spp.*, including *S. typhi*, *S. paratyphi*, *S. choleraesuis*, *S. enteritidis*; *Listeria spp.*, including *L. monocytogenes*; *Helicobacter spp.*, including *H. pylori* (for example urease, catalase, vacuolating toxin); *Pseudomonas spp.*, including *P. aeruginosa*; *Staphylococcus spp.*, including *S. aureus*,

30 *S. epidermidis*; *Enterococcus spp.*, including *E. faecalis*, *E. faecium*; *Clostridium spp.*, including *C. tetani* (for example tetanus toxin and derivative thereof), *C. botulinum* (for example botulinum toxin and derivative thereof), *C. difficile* (for

example clostridium toxins A or B and derivatives thereof); *Bacillus spp.*, including *B. anthracis* (for example botulinum toxin and derivatives thereof); *Corynebacterium spp.*, including *C. diphtheriae* (for example diphtheria toxin and derivatives thereof); *Borrelia spp.*, including *B. burgdorferi* (for example OspA, OspC, DbpA, DbpB), *B. garinii* (for example OspA, OspC, DbpA, DbpB), *B. afzelii* (for example OspA, OspC, DbpA, DbpB), *B. andersonii* (for example OspA, OspC, DbpA, DbpB), *B. hermsii*; *Ehrlichia spp.*, including *E. equi* and the agent of the Human Granulocytic Ehrlichiosis; *Rickettsia spp.*, including *R. rickettsii*; *Chlamydia spp.*, including *C. trachomatis* (for example MOMP, heparin-binding proteins), *C. pneumoniae* (for example MOMP, heparin-binding proteins), *C. psittaci*; *Leptospira spp.*, including *L. interrogans*; *Treponema spp.*, including *T. pallidum* (for example the rare outer membrane proteins), *T. denticola*, *T. hyodysenteriae*; or derived from parasites such as *Plasmodium spp.*, including *P. falciparum*; *Toxoplasma spp.*, including *T. gondii* (for example SAG2, SAG3, Tg34); *Entamoeba spp.*, including *E. histolytica*; *Babesia spp.*, including *B. microti*; *Trypanosoma spp.*, including *T. cruzi*; *Giardia spp.*, including *G. lamblia*; *Leshmania spp.*, including *L. major*; *Pneumocystis spp.*, including *P. carinii*; *Trichomonas spp.*, including *T. vaginalis*; *Schistosoma spp.*, including *S. mansoni*, or derived from yeast such as *Candida spp.*, including *C. albicans*; *Cryptococcus spp.*, including *C. neoformans*.

20

Vaccines of the present invention further comprise peptides derived from parasites that cause Malaria. Peptides may be derived from the circumsporozoite (CS) protein of *P.falciparum*, or TRAP antigens (WO 90/01496). Other plasmodia antigens that are likely candidates to be donors of peptides for a multistage Malaria vaccine are *P. faciparum* MSP1, AMA1, MSP3, EBA, GLURP, RAP1, RAP2, Sequestrin, PfEMP1, Pf332, LSA1, LSA3, STARP, SALSA, PfEXP1, Pfs25, Pfs28, PFS27/25, Pfs16, Pfs48/45, Pfs230 and their analogues in *Plasmodium spp.*

25

The immunogens of the present invention may also contain an anti-tumour peptide and be useful for the immunotherapeutic treatment cancers. For example, the adjuvant formulation finds utility with tumour rejection antigens such as those for prostate, breast, colorectal, lung, pancreatic, renal or melanoma cancers. Exemplary antigens

30

include MAGE 1 and MAGE 3 or other MAGE antigens for the treatment of melanoma (particularly the peptide EVDPIGHL Y (US 5,662,907), PRAME, BAGE or GAGE (Robbins and Kawakami, 1996, Current Opinions in Immunology 8, pps 628-636; Van den Eynde et al., International Journal of Clinical & Laboratory
5 Research (submitted 1997); Correale et al. (1997), Journal of the National Cancer Institute 89, p293. Indeed these antigens are expressed in a wide range of tumour types such as melanoma, lung carcinoma, sarcoma and bladder carcinoma. Other Tumor-Specific antigens are suitable for use with adjuvant of the present invention and include, but are not restricted to Prostate specific antigen (PSA) or Her-2/neu,
10 KSA (GA377), MUC-1 and carcinoembryonic antigen (CEA). Accordingly in one aspect of the present invention there is provided an immunogen comprising a peptide derived from a tumour rejection antigen coupled to protein D.

The ratio of peptide to protein D carrier is typically in the order of between 1:1 to
15 1:20, but preferably between 2 to 10 peptides per Protein D carrier.

Vaccines of the present invention are preferably used for the prophylaxis or therapy of allergy. Such vaccines may comprise allergen specific peptide (for example from Der p1) or allergen non-specific peptides (for example the stanworth decapeptide).

20

Vaccines of the present invention comprise an immunogen as described above and an adjuvant. Suitable adjuvants are well known in the art (Vaccine Design – The Subunit and Adjuvant Approach, 1995, Pharmaceutical Biotechnology, Volume 6, Eds.

Powell, M.F., and Newman, M.J., Plenum Press, New York and London, ISBN 0-306-
25 44867-X).

Preferred adjuvants for use with immunogens of the present invention include: aluminium or calcium salts (hydroxide or phosphate), oil in water emulsions (WO 95/17210, EP 0 399 843), or particulate carriers such as liposomes (WO 96/33739).
30 Immunologically active saponin fractions (e.g. Quil A) having adjuvant activity derived from the bark of the South American tree Quillaja Saponaria Molina are particularly preferred. Derivatives of Quil A, for example QS21 (an HPLC purified

fraction derivative of Quil A), and the method of its production is disclosed in US Patent No.5,057,540. Amongst QS21 (known as QA21) other fractions such as QA17 are also disclosed. 3 De-O-acylated monophosphoryl lipid A is a well known adjuvant manufactured by Ribi Immunochem, Montana. It can be prepared by the methods taught in GB 2122204B. A preferred form of 3 De-O-acylated monophosphoryl lipid A is in the form of an emulsion having a small particle size less than 0.2µm in diameter (EP 0 689 454 B1).

Adjuvants also include, but are not limited to, muramyl dipeptide and saponins such as Quil A, bacterial lipopolysaccharides such as 3D-MPL (3-O-deacylated monophosphoryl lipid A), or TDM. As a further exemplary alternative, the protein can be encapsulated within microparticles such as liposomes, or in non-particulate suspensions of polyoxyethylene ether (UK Patent Application No. 9807805.8). Particularly preferred adjuvants are combinations of 3D-MPL and QS21 (EP 0 671 948 B1), oil in water emulsions comprising 3D-MPL and QS21 (WO 95/17210, PCT/EP98/05714), 3D-MPL formulated with other carriers (EP 0 689 454 B1), or QS21 formulated in cholesterol containing liposomes (WO 96/33739), or immunostimulatory oligonucleotides (WO 96/02555).

Examples of suitable pharmaceutically acceptable excipients include water, phosphate buffered saline, isotonic buffer solutions. The vaccines of the present invention may also be administered via the oral route. In such cases the pharmaceutically acceptable excipient may also include alkaline buffers, or digestible capsules.

The formulations of the present invention maybe used for both prophylactic and therapeutic purposes. Accordingly, the present invention provides for a method of treating a mammal susceptible to or suffering from an infectious disease or cancer, or allergy, or autoimmune disease. In a further aspect of the present invention there is provided a vaccine as herein described for use in medicine. Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978.

In a further aspect of the present invention there is provided an immunogen or vaccine as herein described for use in medicine.

5 The vaccine preparation of the present invention may be used to protect or treat a mammal susceptible to, or suffering from allergies, by means of administering said vaccine via systemic or mucosal route. These administrations may include injection *via* the intramuscular, intraperitoneal, intradermal or subcutaneous routes; or *via* mucosal administration to the oral/alimentary, respiratory, genitourinary tracts.

10 The amount of protein in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 μ g of protein, preferably 1-500 μ g, preferably 1-100 μ g, of which 1
15 to 50 μ g is the most preferable range. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.

20 Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978. Conjugation of proteins to macromolecules is disclosed by Likhite, U.S. Patent 4,372,945 and by Armor et al., U.S. Patent 4,474,757.

25

Example 1, Preparation of peptide/carrier immunogens and vaccine formulations*1.1 Preparation of Protein D for use as a peptide carrier*

Protein D may be produced and purified using methods described in EP 0 594 610 B1.

5

1.2 Preparation of IgE Peptides for conjugation to the carrier

The peptides which have been used in these examples are peptides derived from human or rodent IgE C ϵ 4. These immunogens have previously been shown to be capable of stimulating antibody responses which are capable of inhibiting histamine release from IgE bearing mast cells (EP 0 477 231 B1).

10

Peptides were chemically synthesised by NeoSystem Laboratoire (Strasbourg, France). The immunogen peptide have the sequences represented in the table 1.

15 **Table 1, Peptide sequences**

	<i>Sequence</i>	<i>Source</i>	<i>Molecular Weight</i>
PEP1 (deca)	KTKGSGFFVF-NH ₂	Human IgE	1117.3
PEP2 (deca)	CKTKGSGFFVF-NH ₂	Human IgE	1219.5
PEP3 (dodeca)	CKSNGSNQGFFIF-NH ₂	Rodent IgE	1447.6
PEP4 (dodeca)	KSNGSNQGFFIF-NH ₂	Rodent IgE	1345.4

The peptides were stored dry and frozen at -20°C until used in the conjugation procedure.

20 *1.3 Synthesis of conjugates using a succinimide-maleimide cross-linker*

Protein D may be conjugated directly to peptides to form antigens of the present invention by using a maleimide-succinimide cross-linker. This chemistry allows controlled NH₂ activation of carrier residues by fixing a succinimide group.


Maleimide groups is a cystein-binding site. Therefore, for the purpose of the following examples, the IgE peptides to be conjugated required the addition of an N-terminal cystein (PEP2 and PEP3).

25


The coupling reagent is a selective heterobifunctional cross-linker, one end of the compound activating amino group of the protein carrier by an succinimidyl ester and the other end coupling sulhydryl group of the peptide by a maleimido group. The

5 reactional scheme is as the following :

a. Activation of the protein by reaction between lysine and succinimidyl ester :



10 b. Coupling between activated protein and the peptide cystein by reaction with the maleimido group :



15

1.4 Preparation of peptide PEP2-Protein D conjugate "low ratio"

The protein D is dissolved in a phosphate buffer saline at a pH 7.2 at a concentration
20 of 2.5 mg/ml. The coupling reagent (N-[γ-maleimidobutyryloxy] succinimide ester - GMBS) is dissolved at 102.5 mg/ml in DMSO and added to the protein solution.


1.025 mg of GMBS is used for 1 mg of Protein D. The reactional solution is incubated 1 hour at room temperature. The by-products are removed by a desalting step onto a sephacryl 200HR permeation gel. The eluant used is a phosphate buffer saline Tween 80 0.1 % pH 6.8. The activated protein is collected and pooled. The peptide is
5 dissolved at 4 mg/ml in 0.1 M acetic acid to avoid di-sulfure bond formation. A molar ratio of between 2 to 4 peptides per 1 activated Protein D is used for the coupling. The peptide solution is slowly added to the protein and the mixture is incubated 1 h at 25°C. The pH is kept at a value of 6.6 during the coupling phase. A quenching step is performed by addition of cystein (0.1 mg cystein per mg of activated PD dissolved at
10 4 mg/ml in acetic acid 0.1 M), 30 minutes at 25°C and a pH of 6.5. Two dialysis against NaCl 150 mM Tween 80 0.1 % are performed to remove the excess of cystein or peptide.

The last step is a sterilisant filtration on a 0.22 μ m membrane. The final product is a
15 clear filtrable solution conserved at 4°C. The final ratio of peptide/PD in the construct is determined by Amino acid analysis.

1.5 Preparation of peptide PEP2-Protein D conjugate "high ratio"

20 The activated PD is prepared as in example 1.4. The activated Protein D is passed through a 0.22 μ m membrane. Peptide is also diluted in acetic acid 0.1 M and filtrated on a 0.22 μ m membrane. The two solutions are then slowly mixed to obtain a final molar peptide/Protein D ratio of 8. The pH is adjusted to 6.5. After 1 h at 25°C, the solution is conserved at 4°C.

25 The figure 1, shows the evolution of protein concentration according to increasing initial peptide / Protein D ratio. At a ratio of 4 peptide per 1 PD, the majority of the conjugate is soluble and is, therefore, found in the supernatant. At a ratio 8/1, nearly all of protein content is precipitated. At a higher ratio, the conjugate is precipitated
30 and the excess of unconjugated peptide is found in the supernatant.

Figure 1, Solubility of Protein D/peptide conjugates of different ratios

5

1.6 Production of Oil in Water (o/w) emulsion adjuvants

The oil in water emulsion adjuvant formulations used in the subsequent examples were each made comprising the following oil in water emulsion component: 5%

10 Squalene, 5% α -tocopherol, 2.0% polyoxyethylene sorbitan monooleate (TWEEN 80).

The emulsion was prepared as follows as a 2 fold concentrate. All examples used in the immunological experiments are diluted with the addition of extra components and diluents to give either a 1x concentration (equating to a squalene:QS21 ratio (w/w) of

15 240:1) or further dilutions thereof.

Briefly, the TWEEN 80 is dissolved in phosphate buffered saline (PBS) to give a 2% solution in the PBS. To provide 100 ml of a two fold concentrate emulsion, 5ml of

20 DL α tocopherol and 5ml of squalene are vortexed to mix thoroughly. 95ml of PBS/TWEEN solution is added to the oil and mixed thoroughly. The resulting emulsion is then passed through a syringe needle and finally microfluidised by using

an M110S Microfluidics machine. The resulting oil droplets have a size of approximately 145-180 nm (expressed as z av. measured by PCS) and is termed SB62.

- 5 The other adjuvant/vaccine components (QS21, 3D-MPL or antigen) are added to the emulsion in simple admixture.

1.7 Alum adjuvant may be bought from Superfos.

10 1.8 *ELISA assay to determine anti-antigen antibody responses*

The anti-peptide and anti-carrier immune responses were investigated using an ELISA technique outlined below.

- 15 • Microtiterplates (Nunc) are coated with the specific antigen in PBS (4° overnight) with either:
Streptavidin at 2µg/ml (followed by incubation with biotinylated peptide (1µM) for 1 hour at 37°C), or
KLH, or
20 Protein D.
- Wash 3X PBS-Tween 20 0.1%.
 - Saturate plates with PBS-BSA 1%-Tween 20 0.1% (Sat buffer) for 1 hr at 37°.
 - Add 1° antibody = sera in two-step dilution (in Sat buffer), incubate 1 hr 30 minutes at 37°.
- 25 • Wash 3X.
- Add 2° anti-mouse Ig (or anti-mouse isotype specific monoclonal antibody) coupled to HRP. Incubate 1 hr at 37°.
 - Wash 5X.
 - Reveal with TMB (BioRad) for 10 minutes at room temperature in the dark.
- 30 • Block reaction with 0.4N H₂SO₄.

A monoclonal anti-human decapeptide antibody (Dec7B) was used as reference in deca/dodeca ELISA. This makes it possible to calculate anti-decapeptide antibody responses either in μg specific antibody per 1ml or serum ($\mu\text{g}/\text{ml}$), or as a midpoint titre. Anit-Protein D and anti-KLH responses are calculated as midpoint titers.

5

1.9 Production of peptide-KLH conjugates

Peptide-KLH conjugates were made according to manufacturer's instructions.

Example 2, Immunogenicity studies with Stanworth decapeptide conjugates adsorbed onto alum.

10

Three groups of 10 Balb/C mice were vaccinated with the PEP2 human decapeptide – protein D conjugates produced according to the methods described in example 1. The vaccines comprised 25 μg of antigen in 100 μl volumes, and were given s.c on three occasions on days 0, 21, and 42 (V1, V2, and V3).

15

Table 3, *Vaccine compositions*

<i>Name of group</i>	<i>Number of peptide:Protein D</i>	<i>Adjuvant</i>
ProtD-Deca 007	2	Al(OH) ₃ (100 µg)
ProtD-Deca 008	8	Al(OH) ₃ (100 µg)
KLH-Deca	5	Al(OH) ₃ (100 µg)


Bleedings were taken 21, 35, and 49 days post commencement of immunisation (21 post V1, 14 post V2, and 7 post V3).

5

The results for generation of antibody responses are shown in Table 4 for individual responses at time points 21 post V1, 14 post V2, and 7 post V3. Figure 2 (anti-decapeptide IgG responses and anti-carrier IgG responses) shows the comparison of the antibody responses induced by the three vaccines in pooled sera.

10

Figure 2, Total anti-decapeptide and anti-carrier IgG (Mid point titre)



The isotype of the antibodies produced was investigated in the ELISA system using anti-mouse isotype monoclonal antibodies (see table 5). These studies were performed on pooled serum samples.

5 **Table 5**, Anti-decapeptide responses generated by antigen conjugates adsorbed onto alum (7 post V3)

	<i>Anti-Decapeptide ($\mu\text{g/ml}$)</i>				<i>Isotype %</i>		
	<i>IgG1</i>	<i>IgG2a</i>	<i>IgG2b</i>	<i>total</i>	<i>IgG1</i>	<i>IgG2a</i>	<i>IgG2b</i>
<i>ProtD-Deca 007</i>	59	0	0	59	100	0	0
<i>ProtD-Deca 008</i>	151	0	0	151	100	0	0
<i>KLH-Deca</i>	10	0	0	10	100	0	0

10 The ratio's of Mid-point titres of anti-peptide:anti-carrier IgG responses were measured (results see table 6). This ratio is a measure of the relative levels of anti-peptide or anti-carrier immune response which were generated by vaccination. A high ratio (>1) indicates that strong anti-peptide response is being generated with respect to that induced against the carrier.

15 **Table 6**, Midpoint titers and ratio anti-deca versus anti-carrier response

Time point	Vaccine formulation	Titre Mid point		ratio
		IgG anti Deca	IgG anti carrier	IgG anti Deca : IgG anti Carrier
21 Post 1	KLH-Deca / Alum	5	1155	0.005
	ProtD-Deca 007 / Alum	17	351	0.05
	ProtD-Deca 008 / Alum	15	48	0.32
14 Post 2	KLH-Deca / Alum	166	75222	0.002
	ProtD-Deca 007 / Alum	1260	24085	0.05
	ProtD-Deca 008 / Alum	2522	683	3.7
7 Post 3	KLH-Deca / Alum	495	63580	0.008

	ProtD-Deca 007 / Alum	3113	24889	0.13
	ProtD-Deca 008 / Alum	7313	1571	4.7

Conclusions

IgE peptide conjugated to Protein D was capable of inducing strong anti-peptide immune responses when adjuvanted with alum. The protein D conjugates induced greater anti-peptide responses compared with those induced by the KLH conjugates, whilst inducing less anti-carrier responses than that induced by the KLH conjugates.

ProteinD-IgE peptide conjugates with a ratio of (8:1 peptide:carrier) performed better than those with a ratio of 2:1, in both the magnitude of the anti peptide IgG response and the relative proportions of peptide:carrier IgG responses. The conjugates with a ratio of 2:1 (peptide:carrier) nevertheless performed better than KLH in these respects.

Example 3, Immunogenicity studies with Stanworth decapeptide conjugates formulated with oil in water adjuvants

Three groups of 10 Balb/C mice were vaccinated with the human decapeptide conjugates produced according to the methods described in example 1 and 2. The vaccines comprised 25µg of antigen formulated with an oil in water emulsion adjuvant (produced as described in example 1.8) in 100µl volumes, and were given s.c on three occasions on days 0, 21, and 42 (V1, V2, and V3).


Table 7, Vaccine formulations in example 3.

Name of group	Number of peptide:carrier	Adjuvant
ProtD-Deca 007	2	O/W emulsion, 3D-MPL (2 µg), QS21 (5 µg)
ProtD-Deca 008	8	O/W emulsion, 3D-MPL (2 µg), QS21 (5 µg)
KLH-Deca	5	O/W emulsion, 3D-MPL (2 µg), QS21 (5 µg)

Bleedings were taken 21, 35, and 49 days post commencement of immunisation (21 post V1, 14 post V2, and 7 post V3).

5 The results for generation of antibody responses are shown in Table 8 for individual responses at time points 21 post V1, 14 post V2, and 7 post V3. Figure 3 (anti-decapeptide antibody responses and anti-carrier antibody responses) shows the comparison of the antibody responses induced by the three vaccines in pooled sera.

Figure 3, Total anti-decapeptide and anti-carrier Ig (Mid point titre) with vaccines comprising oil in water emulsion adjuvants.



The isotype of the antibodies produced was investigated in the ELISA system using anti-mouse isotype monoclonal antibodies (see table 9). These studies were performed on pooled serum samples.

Table 9, Anti-decapeptide responses generated by antigen conjugates formulated with oil in water emulsion adjuvants (7 post V3)

	<i>Anti-Decapeptide ($\mu\text{g/ml}$)</i>				<i>Isotype %</i>		
	<i>IgG1</i>	<i>IgG2a</i>	<i>IgG2b</i>	<i>total</i>	<i>IgG1</i>	<i>IgG2a</i>	<i>IgG2b</i>
<i>ProtD-Deca 007</i>	223	52	22	296	75	17	7
<i>ProtD-Deca 008</i>	354	10	5	369	96	3	1
<i>KLH-Deca</i>	202	61	47	311	65	20	15

The ratio's of Mid-point titres of anti-peptide:anti-carrier IgG responses were measured (results see table 10). This ratio is a measure of the relative levels of anti-peptide or anti-carrier immune response which were generated by vaccination. A high ratio (>1) indicates that strong anti-peptide response is being generated with respect to that induced against the carrier.

Table 10, Midpoint titers and ratio anti-deca versus anti-carrier response

Time point	Vaccine formulation	Titre Mid point		Ratio
		IgG anti Deca	IgG anti carrier	IgG anti Deca : IgG anti carrier
21 Post 1	KLH-Deca / SBAS2	1811	239520	0.01
	ProtD-Deca 007 / SBAS2	1118	1343	0.8
	ProtD-Deca 008 / SBAS2	3641	1718	2.1
14 Post 2	KLH-Deca / SBAS2	24641	521684	0.05
	ProtD-Deca 007 / SBAS2	23319	27170	0.9
	ProtD-Deca 008 / SBAS2	36130	21601	1.7

7 Post 3	KLH-Deca / SBAS2	21260	336431	0.06
	ProtD-Deca 007 / SBAS2	26012	23615	1.1
	ProtD-Deca 008 / SBAS2	22759	11968	1.9

Conclusions

IgE peptide conjugated to Protein D was capable of inducing strong anti-peptide immune responses when adjuvanted with oil in water emulsions. The protein D conjugates induced greater anti-peptide responses compared with those induced by the KLH conjugates, whilst inducing less anti-carrier responses than that induced by the KLH conjugates.

10

Example 4, Immunogenicity studies with dodecapeptide conjugates adsorbed onto alum

The dodeca-peptide used in this example (PEP3) is the rodent equivalent of the human IgE peptide used previously (PEP2). This example, therefore, examines the use of ProteinD-IgE peptide conjugates in a self-antigen model. The conjugates were formulated as described in examples 1.4 and 1.5 above.

The vaccines comprised 25µg of antigen formulated with an alum adjuvant in 100µl volumes, and were given s.c. on three occasions on days 0, 21, and 42 (V1, V2, and V3).

20

Table 11, *Vaccine compositions*

<i>Name of group</i>	<i>Number of peptide:ProtD</i>	<i>Adjuvant</i>
ProtD-Deca 007	2	Al(OH) ₃ (100 µg)
ProtD-Deca 008	8	Al(OH) ₃ (100 µg)

Bleedings were taken 21, 35, and 49 days post commencement of immunisation (21 post V1, 14 post V2, and 7 post V3). The ratio's of Mid-point titres of anti-

peptide:anti-carrier IgG responses were measured (results see table 12). This ratio is a measure of the relative levels of anti-peptide or anti-carrier immune response which were generated by vaccination. A high ratio (>1) indicates that strong anti-peptide response is being generated with respect to that induced against the carrier.

5

Table 12, Midpoint titers and ratio anti-deca versus anti-carrier response

Time Point	Vaccine formulation	Titre Mid point		Ratio
		IgG anti Dodeca	IgG anti carrier	IgG anti dodeca : IgG anti carrier
21 Post 1	ProtD - Dodeca 007	1	168	0.006
	ProtD - Dodeca 008	230	113	2.04
14 Post 2	ProtD - Dodeca 007	6	9970	0.001
	ProtD - Dodeca 008	1961	4791	0.41
7 Post 3	ProtD - Dodeca 007	205	21573	0.009
	ProtD - Dodeca 008	2980	8826	0.34

Conclusions

ProteinD-dodeca peptide conjugates adsorbed onto alum are capable of inducing anti-peptide immune responses in the context of a self-antigen model. In this respect the high ratio conjugate performed better than the low ratio construct.

Example 5, Immunogenicity studies with dodecapeptide conjugates formulated with oil in water adjuvants

The dodeca-peptide used in this example (PEP3) is the rodent equivalent of the human IgE peptide used previously (PEP2). This example, therefore, examines the use of ProteinD-IgE peptide conjugates in a self-antigen model. The conjugates were formulated as described in examples 1.4 and 1.5 above.

The vaccines comprised 25µg of antigen formulated with an oil in water emulsion adjuvant (produced according to example 1.8) in 100µl volumes, and were given s.c. on three occasions on days 0, 21, and 42 (V1, V2, and V3).

5 Table 13, *Vaccine compositions*

<i>Name of group</i>	<i>Number of peptide:ProtD</i>	<i>Adjuvant</i>
ProtD-Deca 007	2	O/W emulsion, 3D-MPL (2 µg), QS21 (5 µg)
ProtD-Deca 008	8	O/W emulsion, 3D-MPL (2 µg), QS21 (5 µg)

Bleedings were taken 21, 35, and 49 days post commencement of immunisation (21 post V1, 14 post V2, and 7 post V3). The ratio's of Mid-point titres of anti-peptide:anti-carrier IgG responses were measured (results see table 14). This ratio is a
 10 measure of the relative levels of anti-peptide or anti-carrier immune response which were generated by vaccination. A high ratio (>1) indicates that strong anti-peptide response is being generated with respect to that induced against the carrier.

Table 14, Midpoint titers and ratio anti-dodeca versus anti-carrier response

Time Point	Vaccine formulation	Titre Mid point		ratio
		IgG anti Dodeca	IgG anti carrier	IgG anti Dodeca : IgG anti protD
21 Post 1	ProtD - Dodeca 007 / SBAS2	219	828	0.26
	ProtD - Dodeca 008 / SBAS2	11195	3645	3.07
14 Post 2	ProtD - Dodeca 007 / SBAS2	6811	14628	0.47
	ProtD - Dodeca 008 / SBAS2	43173	20194	2.14
7 Post 3	ProtD - Dodeca 007 / SBAS2	13392	22595	0.59
	ProtD - Dodeca 008 / SBAS2	22008	17507	1.26

15

Conclusions

ProteinD-dodeca peptide conjugates adsorbed onto alum are capable of inducing anti-peptide immune responses in the context of a self-antigen model. In this respect the high ratio conjugate performed better than the low ratio construct.

5

Example 6, Immunogenicity studies with Stanworth decapeptide conjugates in mice

Groups of Balb/C mice were vaccinated in order to further investigate the benefits of the Protein D carrier over the use of KLH. Briefly, groups of 10 mice were vaccinated on three occasions with on days 0, 21 and 42 with vaccines conjugated, formulated and inoculated according to Table 15.

Bleeds were taken on days 35 and 56. Results for anti-peptide IgG responses are shown in Figure 4 and anti-carrier IgG responses are shown in Figure 5.

15 The anti-peptide and anti-carrier immune responses were investigated using an ELISA described in section 1.8.


Table 15, Vaccine formulations (all groups adjuvanted with alum (100µg))

Group	Antigen	Ratio peptide:carrier	Immunisation route
1	PD/deca	8	subcut
2	PD/deca	8	intramuscular
3	PD/deca	4	subcut
4	PD/deca	4	intramuscular
5	KLH/deca	5	subcut
6	KLH/deca	5	intramuscular


Groups 1 -2 and 3-4 were produced as described in examples 1.5 and 1.4. Group 5-6 was produced as described in example 1.9

20

Figure 4, Anti-decapeptide IgG response



5 Figure 5, Anti-Carrier IgG response



Example 7 Immunogenicity studies with decapeptide conjugates in monkeys

Two groups of 5 Rhesus monkeys were vaccinated respectively with the PEP2 human decapeptide-protein D ,conjugates produced and formulated as described in example 5 1.4 and with PEP2 human decapeptide-KLH, conjugates produced and formulated as described in example 1.11.

The vaccine comprised 250µg of antigen in 1ml and were given on three occasions on day 0, 28 and 56.


Bleeds were taken on day 28, 42 and 70.

10 The anti-peptide responses were investigated using an ELISA described in section 1.8 (but the second reagent used is an anti-human IgG instead of an anti-mouse IgG). Results for anti-peptide IgG response (days 28 and 42) are shown in Figure 6.

Conclusions.

15 IgE peptide conjugated to Protein D induced a significantly greater anti-peptide response compared to the titer induced by the KLH conjugate.

Figure6, Anti-decapeptide IgG response.



Claims

1. An immunogen comprising a peptide and a carrier, characterised in that said carrier is Protein D from Haemophilus Influenzae, or immunologically equivalent thereof.
- 5 2. An immunogen as claimed in claim 1, wherein said derivative of protein D is Protein D 1/3rd.
3. An immunogen as claimed in claim 1, wherein said peptide is derived from IgE.
4. An immunogen as claimed in claim 1, wherein said peptide is GnRH.
5. An immunogen as claimed in claim 1, comprising a peptide derived from the
- 10 antigens defined in the specification.
6. A vaccine comprising an immunogen as claimed in claim 1, and an adjuvant.
7. A vaccine as claimed in claim 6, wherein the adjuvant one of the following group comprising : QS21, 3D-MPL, oil in water emulsions, alpha-tocopherol, CpG, polyoxyethylene ether, aluminium or calcium salts.
- 15 8. A nucleic acid molecule, said molecule encoding an immunogen of claim 1.
9. Use of Protein D in the manufacture of immunogens as described in claim 1.
10. Use of an immunogen as claimed in claim 1, in the manufacture of a medicament for the prevention or treatment of disease or allergy.
11. An immunogen or vaccine as claimed herein for use in medicine.

THIS PAGE BLANK (USPTO)